If anyone needed proof that the GLP-1 revolution in medicine is nowhere close to slowing down, Eli Lilly just delivered it in the form of a single quarter that left Wall Street’s expectations well behind. The Indianapolis-based pharmaceutical company reported first-quarter 2026 revenue of $19.8 billion today, a 56% increase compared to the same period […]
The postEli Lilly crushes Q1 with $19.8B and a critical new drugappeared first onRolling Out.



